Digital Health New York’s Healthcare Innovation Report analyzes the investment trends, opportunities and challenges in New York’s evolving digital health sector.
This issue features insights from 30+ founders, investors, providers and thought leaders. They discuss topics ranging from the founder-funder dynamic to the implementation of AI to predictions for 2026. And not to be missed – we present the 2026 Digital Health 100 (DH100), a list of the most exciting and innovative health startups in the New York region.

NewYorkBIO appointed the 2026 Board of Directors representing various sectors and share a commitment to advancing the growth of New York’s statewide life science industry.
The new class of leaders includes Andrew Lam of Ally Bridge Group,Theresa Mazzullo of Excell Partners, Monica Shaw of Bristol Myers Squibb and Julia Nanyi Zhao, PhD of BioLabs@NYU.
The following board members were reelected to serve another three-year term: Rana Al-Hallaq llaq of Pfizer Ventures, Matt Badalucco of Merck, Dawn Bell of Kardigan.Bio, Lis Leiderman, MD,
Robert Van Nostrand a Veteran Biotech CFO, Manan Shah of 1619 Advisors and Alan Tamarelli of Cooley LLP.

Authored by Andre O. Hudson, Dean of the College of Science, Professor of Biochemistry, Rochester Institute of Technology, this article underscores both the urgency of the antibiotic resistance crisis and the innovations that offer real hope from faster diagnostics and novel therapeutic approaches to stronger policies and improved stewardship.